# Quanta Dialysis Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quanta-dialysis-technologies

- Industry: Medical Devices & Equipment
- Headquarters: UK
- Website: www.quantadt.com
- Total disclosed funding: $366M
- Latest round: Series E (Nov 13, 2024)
- Investors on record: 16

## About

Founded in 2008 by John E. Milad, and based in the UK, Quanta Dialysis Technologies Limited, formerly known as Quanta Fluid Solutions Ltd., operates as a medical device company that offers haemodialysis machines for dialysis patients. In June 2021, Quanta Dialysis Technologies Limited, raised GBP 175.92 million in series D funding, co-led by Glenview Capital and Novo Holdings, with participation from other new investors: Ancora Capital Management, BlackRock, Eldridge Industries, Millennium Management, Monashee Investment Management, Orlando Health Ventures, Puhua Capital, Sands Capital Ventures, and Segulah.

The company offers a haemodialysis machine, SC+, that helps patients to control their disease and determine the treatment regime and care. It helps patients transition from nurse-assisted treatment to self-care in the center to home haemodialysis by facilitating a smooth transition between treatment modalities on a physician's list of treatment options. The company also provides a cloud-based digital health platform that offers dialysate fluid management solutions, management of treatment data, remote patient monitoring, and technical support.

The company's revenue is generated by the sales of its medical device called SC+ to dialysis patients and other related markets.

## Funding rounds

- Series E, Nov 13, 2024, $59M — Novo Holdings, Glenview Capital Management, b2venture
- Series D, Jun 18, 2021, $245M — Wellington Partners, Seroba, Glenview Capital Management, Ancora Capital Management, Millennium Management, BlackRock, b2venture, Grand Angels, Novo Holdings, Monashee Investment Management, Sands Capital Alternatives, Puhua Capital, Eldridge Industries, Orlando Health Ventures, Segulah Medical Acceleration
- Series C, Jul 29, 2019, $47M — Wellington Partners, Seroba, b2venture
- Series A, Sep 29, 2009, $15M — Wellington Partners, Seroba, Stage Capital, b2venture

## Investors

- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series A, Series C, Series D
- Seroba (https://capitalatlas.ai/funds/seroba) — Series A, Series C, Series D
- Stage Capital (https://capitalatlas.ai/funds/stage-capital) — Series A
- b2venture (https://capitalatlas.ai/funds/b2venture) — Series A, Series C, Series D, Series E
- Glenview Capital Management — Series D, Series E
- Ancora Capital Management (https://capitalatlas.ai/funds/ancora-capital-management) — Series D
- Millennium Management — Series D
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series D
- Grand Angels — Series D
- Novo Holdings — Series D, Series E
- Monashee Investment Management — Series D
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series D
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series D
- Eldridge Industries (https://capitalatlas.ai/funds/eldridge-industries) — Series D
- Orlando Health Ventures — Series D
- Segulah Medical Acceleration (https://capitalatlas.ai/funds/segulah-medical-acceleration) — Series D